The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2021 RFP: Outcome Measures, 2022Use of Integrated, Multi-omic Data Analysis for Screening and Treatment of Parkinson’s Disease
Study Rationale: Current diagnostic criteria and treatment options are designed for the “average” person with Parkinson’s disease (PD). This one-size-fits-all approach ignores the huge biological and...
-
Summer 2021 RFP: Expanding Biological Understanding of PD, 2021Assessment of LRRK2 Activity and Neurodegeneration Markers in Postmortem Brain Samples of Idiopathic and LRRK2-associated Parkinson’s Disease
Study Rationale: Genetic variance at the LRRK2 gene locus is associated with risk of Parkinson’s disease (PD). Most evidence suggests that this variation increases the activity of the encoded LRRK2...
-
Fall 2021 RFP: Expanding Biological Understanding of PD, 2022Evaluation of Gene Products that Counteract the Action of LRRK2
Study Rationale: Although most cases of Parkinson’s disease (PD) are of unknown origin, some forms can be inherited. Mutations that activate the enzyme LRRK2 are a major cause of inherited PD, and...
-
Fall 2021 RFP: Outcome Measures, 2022Development of Standardized Measurements for Monitoring the Progression of Parkinson’s Disease via MRI
Study Rationale: One of the difficulties in research towards new treatments in Parkinson’s disease (PD) is the diversity of disease presentations and the lack of tools to measure the effect of a...
-
Fall 2021 RFP: Outcome Measures, 2021Development of Novel Antibodies that Facilitate the Accurate Measurement of All Forms of Alpha-synuclein Present in Biological Fluids
Study Rationale: The ability to accurately detect and quantify alpha-synuclein and its pathology-relevant variants represents a major challenge in Parkinson’s disease (PD). Different studies report...
-
Target Advancement Program, 2021Enhancing Treatment Efficacy by Eliminating L-dopa Metabolizing Gut Bacteria
Study Rationale: Levodopa (L-dopa) is the primary medication used to treat Parkinson’s disease (PD). For L-dopa to exert its effect, it must enter the brain and be converted to the chemical dopamine...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.